Pharmaxx: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharmaxx
Largest movements
- Receivables within one year +€46,532
up €46,532 (+74.6%), from €62,396 to €108,929
of which Trade receivables: +€47,468
- Cash -€9,956
down €9,956 (-67.1%), from €14,829 to €4,873
mainly Receivables within one year (-€46,532) and Tax, wage and social debts (-€557)
- Reserves +€14,435
up €14,435 (+48.1%), from €30,001 to €44,437
- Accrued charges and deferred income +€9,864
new in 2025: €9,864
- Trade debts +€8,033
up €8,033 (+39.9%), from €20,124 to €28,157
- Other debts +€4,800
up €4,800 (+50.0%), from €9,600 to €14,400
- Gross operating margin -€19,207
down €19,207 (-49.2%), from €39,001 to €19,794
- Taxes -€3,709
down €3,709 (-49.5%), from €7,500 to €3,791
- Other operating charges +€1,299
up €1,299 (+1129.1%), from €115 to €1,414
- Depreciation -€1,222
down €1,222 (-100.0%), from €1,222 to €0
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €77,225 | €113,801 | +€36,576 | +47.4% |
| Current assets | 29/58 | €77,225 | €113,801 | +€36,576 | +47.4% |
| Amounts receivable within one year | 40/41 | €62,396 | €108,929 | +€46,532 | +74.6% |
| Trade receivables | 40 | €61,460 | €108,929 | +€47,468 | +77.2% |
| Other amounts receivable | 41 | €936 | €0 | -€936 | -100.0% |
| Cash at bank and in hand | 54/58 | €14,829 | €4,873 | -€9,956 | -67.1% |
| Total equity and liabilities | 10/49 | €77,225 | €113,801 | +€36,576 | +47.4% |
| Equity | 10/15 | €40,001 | €54,437 | +€14,435 | +36.1% |
| Contributions | 10/11 | €10,000 | €10,000 | = | 0.0% |
| Reserves | 13 | €30,001 | €44,437 | +€14,435 | +48.1% |
| Distributable reserves | 133 | €30,001 | €44,437 | +€14,435 | +48.1% |
| Amounts payable | 17/49 | €37,224 | €59,364 | +€22,140 | +59.5% |
| Amounts payable within one year | 42/48 | €37,224 | €49,500 | +€12,276 | +33.0% |
| Trade debts | 44 | €20,124 | €28,157 | +€8,033 | +39.9% |
| Suppliers | 440/4 | €20,124 | €28,157 | +€8,033 | +39.9% |
| Taxes, remuneration and social security | 45 | €7,500 | €6,943 | -€557 | -7.4% |
| Taxes | 450/3 | €7,500 | €6,943 | -€557 | -7.4% |
| Other amounts payable | 47/48 | €9,600 | €14,400 | +€4,800 | +50.0% |
| Accrued charges and deferred income | 492/3 | - | €9,864 | +€9,864 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,222 | €0 | -€1,222 | -100.0% |
| Other operating charges | 640/8 | €115 | €1,414 | +€1,299 | +1129.1% |
| Gross operating margin | 9900 | €39,001 | €19,794 | -€19,207 | -49.2% |
| Operating profit (loss) | 9901 | €37,664 | €18,380 | -€19,284 | -51.2% |
| Financial income | 75/76B | €0 | €0 | -€0 | -100.0% |
| Recurring financial income | 75 | €0 | €0 | -€0 | -100.0% |
| Financial charges | 65/66B | €163 | €154 | -€9 | -5.3% |
| Recurring financial charges | 65 | €163 | €154 | -€9 | -5.3% |
| Profit (loss) for the period before taxes | 9903 | €37,502 | €18,227 | -€19,275 | -51.4% |
| Income taxes | 67/77 | €7,500 | €3,791 | -€3,709 | -49.5% |
| Profit (loss) for the period | 9904 | €30,001 | €14,435 | -€15,566 | -51.9% |
| Profit (loss) for the period to be appropriated | 9905 | €30,001 | €14,435 | -€15,566 | -51.9% |
Source: filed annual accounts (NBB), fiscal years ended 31 March 2024 and 31 March 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.